Apollomics EV/OCF

What does Apollomics do? Apollomics, Inc. generates revenue through the development and potential commercialization of oncology therapies. The company focuses on discovering and developing drug candidates such as vebreltinib (APL-101), a c-Met inhibitor for non-small cell lung cancer, and uproleselan (APL-106), an E-Selectin antagonist for acute myeloid leukemia. These therapies are in clinical-stage development, with vebreltinib currently in a Phase II multicohort trial. Apollomics targets medical needs in oncology, particularly for patients with advanced tumors and hematologic cancers, aiming to combine their therapies with existing treatment options to enhance immune response and target molecular pathways. The company's pipeline includes nine drug candidates, six of which are in clinical development. Apollomics' lead programs, vebreltinib and uproleselan, are designed to address unmet medical needs in specific cancer types. The firm's strategy involves leveraging these candidates to form partnerships or secure licensing agreements with pharmaceutical companies for further development and commercialization. Apollomics aims to advance its pipeline to generate future revenue streams through successful clinical outcomes and regulatory approvals. Apollomics, Inc. is a clinical-stage biotechnology company headquartered in Foster City, California, with an IPO in 2021. The company's focus on oncology therapies positions it to attract interest from pharmaceutical partners and investors seeking innovative cancer treatments. By developing therapies that target specific molecular pathways and can be combined with standard treatments, Apollomics targets a segment of patients requiring advanced oncology solutions with unmet needs. Apollomics is one of the most popular companies on Eulerpool.